Extracellular Vesicles and Neurodegenerative Diseases
Open accessAbstract
Extracellular vesicles (EVs) include exosomes and microvesicles and have been shown to have roles in the CNS ranging from the removal of unwanted biomolecules to intercellular communication to the spread of pathogenic proteins associated with neurodegenerative diseases. EVs carry protein, lipid, and genetic cargo, and research over more than a decade has shown that they contain the misfolded forms of proteins associated with Alzheimer's, Parkinson's, and the prion diseases. Altered genetic cargo, usually in the form of miRNAs, have also been identified in EVs patients with these diseases, suggesting that EVs may be a source of disease biomarkers. Whether EVs play a key role in the pathogenesis of neurological diseases remains to be firmly established because most current research is performed using cell culture and transgenic animal models. If EVs are identified as a key pathological contributor to neurological conditions, they will form a novel target for therapeutic intervention. This Dual Perspectives article will discuss the current understanding of the role of EVs in neurological diseases and raise some of the limitations of our current understandings of this field. Dual Perspectives Companion Paper: NeuroEVs: Characterizing Extracellular Vesicles Generated in the Neural Domain, by Christie D. Fowler
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Neurodegenerative diseases, such as AD characterized by Aβ and tau accumulation, PD associated with α-synuclein aggregates, and ALS marked by SOD1 misfolding, are increasingly understood in the context of sEVs involvement.
“Neurodegenerative diseases, such as AD characterized by Aβ and tau accumulation, PD associated with α-synuclein aggregates, and ALS marked by superoxide dismutase 1 (SOD 1) misfolding, are increasingly understood in the context of sEVs involvement [45, 113, 129].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [129]
Cites
Théry, C., Witwer, K. W., Aikawa, E., Alcaraz, M. J., Anderson, J. D., Andriantsitohaina, R., Antoniou, A., Arab, T., Archer, F., Atkin‐Smith, G. K., et al. (2018) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2018.1535750 · Cited by 11,099 · see citing works
Self-citationKowal, J., Arras, G., Colombo, M., Jouve, M., Morath, J. P., Primdal-Bengtson, B., Dingli, F., Loew, D., Tkach, M., & Théry, C. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1521230113 · Cited by 3,426 · see citing works
Fiandaca, M. S., Kapogiannis, D., Mapstone, M., Boxer, A., Eitan, E., Schwartz, J. B., Abner, E. L., Petersen, R. C., Federoff, H. J., Miller, B. L., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.06.008 · Cited by 959 · see citing works
Exosomes are released by cultured cortical neurones
Fauré, J., Lachenal, G., Court, M., Hirrlinger, J., Chatellard-Causse, C., Blot, B., Grange, J., Schoehn, G., Goldberg, Y., Boyer, V., et al. (2006) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2005.12.003 · Cited by 896 · see citing works
Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers
Sardar Sinha, M., Ansell-Schultz, A., Civitelli, L., Hildesjö, C., Larsson, M., Lannfelt, L., Ingelsson, M., & Hallbeck, M. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1868-1 · Cited by 527 · see citing works
Goetzl, E. J., Abner, E. L., Jicha, G. A., Kapogiannis, D., & Schwartz, J. B. (2018) · The FASEB Journal · doi:10.1096/fj.201700731r · Cited by 219 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Primary cilia and ciliary signaling pathways in aging and age-related brain disorders
Ma, R., Kutchy, N. A., Chen, L., Meigs, D. D., & Hu, G. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2021.105607 · Cited by 114 · see citing works
Extracellular vesicles as personalized medicine
Beetler, D. J., Di Florio, D. N., Bruno, K. A., Ikezu, T., March, K. L., Cooper, L. T., Wolfram, J., & Fairweather, D. (2023) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101155 · Cited by 101 · see citing works
Different sourced extracellular vesicles and their potential applications in clinical treatments
Bahmani, L., & Ullah, M. (2022) · Cells · doi:10.3390/cells11131989 · Cited by 83 · see citing works
Beretta, C., Nikitidou, E., Streubel-Gallasch, L., Ingelsson, M., Sehlin, D., & Erlandsson, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-72355-2 · Cited by 71 · see citing works
Extracellular vesicle proteome unveils cathepsin B connection to Alzheimer’s disease pathogenesis
Yuyama, K., Sun, H., Fujii, R., Hemmi, I., Ueda, K., & Igeta, Y. (2024) · Brain · doi:10.1093/brain/awad361 · Cited by 47 · see citing works
Sancandi, M., Uysal-Onganer, P., Kraev, I., Mercer, A., & Lange, S. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21082743 · Cited by 41 · see citing works
“EVs are a recognized contributor to neurodegenerative diseases, and both neurotoxic and neuroprotective roles via distribution of EV-mediated cargo, including microRNAs and misfolded proteins, have been implicated [16,17].”
BackgroundExtracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions
Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B. (2024) · Nano Convergence · doi:10.1186/s40580-024-00426-5 · Cited by 26 · see citing works
Pereira, D. R., Silva, E. R., Carvalho-Maia, C., Monteiro-Reis, S., Lourenço, C., Calisto, R., Teixeira, R. J., Carlson, L. E., Bart, G., Vainio, S. J., et al. (2022) · Trials · doi:10.1186/s13063-022-06045-x · Cited by 6 · see citing works
- Authors
- Hill, A. F.
- Affiliations
- La Trobe University (AU)
- Corresponding author
- Hill, Andrew F.
- ORCID
- Hill, Andrew F.
- Venue
- The Journal of Neuroscience
- Publisher
- Society for Neuroscience
- Published
- 2019-11-20
- Volume
- 39
- Issue
- 47
- Pages
- 9269-9273
- ISSN
- 0270-6474 (ISSN-L)
- 1529-2401
- PMC
- PMC6867808
- OpenAlex
- W2991169791
- Cited by
- 437
- References
- 6
- Citations by year
- 2026: 42 · 2025: 66 · 2024: 79 · 2023: 84 · 2022: 87 · 2021: 52 · 2020: 26
- FWCI
- 13.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Journal of Neuroscience (publishedVersion, cc-by-nc-sa)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Victoria University Research Repository (Victoria University) (submittedVersion)
- Figshare (submittedVersion)
- Funders
- Medical Research Council
- Australian Research Council (DP170102312)
- National Health and Medical Research Council (1132604)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Keywords
- extracellular vesicles, exosomes, microvesicles, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, prion disease, protein misfolding, intercellular communication, microRNA, disease biomarkers, therapeutic target
- MeSH terms
- Extracellular Vesicles, Animals, Brain, Cell Communication, Humans, Neurodegenerative Diseases, Exosomes
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
